Evogene Ltd. - Understand $evgn stock

$EVGN Market Cap: $7.834 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$7.478M

TTM

Gross Margin

51.2%

TTM

Net Earnings

-$23.51M

TTM

Current Assets

$25.36M

Q3 2024

Current Liabilities

$23.29M

Q3 2024

Current Ratio

108.89%

Q3 2024

Total Assets

$40.11M

Q3 2024

Total Liabilities

$44.46M

Q3 2024

Book Value

-$4.343M

Q3 2024

Cash

$11.32M

Q3 2024

P/E

-0.3332

Nov 29, 2024 EST

Free Cash Flow

-$20.81M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$5.640M	$1.675M	$930.0K	$1.040M	$750.0K	$1.750M	$3.380M	$6.540M	$11.13M	$14.51M	$17.58M	$17.07M	$14.90M	$12.56M	$9.990M	$3.640M	$250.0K
YoY Change	236.72%	80.11%	-10.58%	38.67%	-57.14%	-48.22%	-48.32%	-41.24%	-23.29%	-17.46%	2.99%	14.56%	18.63%	25.73%	174.45%	1356.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$5.640M	$1.675M	$930.0K	$1.040M	$750.0K	$1.750M	$3.380M	$6.540M	$11.13M	$14.51M	$17.58M	$17.07M	$14.90M	$12.56M	$9.990M	$3.640M	$250.0K
Cost Of Revenue	$1.692M	$909.0K	$6.476M	$570.0K	$330.0K	$2.700M	$4.480M	$7.760M	$9.760M	$10.64M	$10.42M	$9.550M	$8.770M	$5.810M	$4.960M	$1.500M	$50.00K
Gross Profit	$3.948M	$766.0K	-$5.546M	$470.0K	$420.0K	-$950.0K	-$1.100M	-$1.220M	$1.370M	$3.870M	$7.160M	$7.520M	$6.140M	$6.750M	$5.030M	$2.140M	$200.0K
Gross Profit Margin	70.0%	45.73%	-596.34%	45.19%	56.0%	-54.29%	-32.54%	-18.65%	12.31%	26.67%	40.73%	44.05%	41.21%	53.74%	50.35%	58.79%	80.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Selling, General & Admin	$9.679M	$10.42M	$10.81M	$7.990M	$5.660M	$6.610M	$6.930M	$6.620M	$7.100M	$7.490M	$6.540M	$3.900M	$3.830M	$3.130M	$2.200M	$2.210M	$1.320M
YoY Change	-7.07%	-3.69%	35.34%	41.17%	-14.37%	-4.62%	4.68%	-6.76%	-5.21%	14.53%	67.69%	1.83%	22.36%	42.27%	-0.45%	67.42%
% of Gross Profit	245.16%	1359.66%		1700.0%	1347.62%				518.25%	193.54%	91.34%	51.86%	62.38%	46.37%	43.74%	103.27%	660.0%
Research & Development	$20.78M	$20.79M	$12.93M	$17.29M	$13.05M	$11.77M	$12.04M	$11.56M	$10.66M	$10.33M	$8.220M	$5.860M	$4.500M	$4.890M	$2.570M	$4.330M	$2.790M
YoY Change	-0.07%	60.8%	-25.22%	32.49%	10.88%	-2.24%	4.15%	8.44%	3.19%	25.67%	40.27%	30.22%	-7.98%	90.27%	-40.65%	55.2%
% of Gross Profit	526.27%	2714.36%		3678.72%	3107.14%				778.1%	266.93%	114.8%	77.93%	73.29%	72.44%	51.09%	202.34%	1395.0%
Depreciation & Amortization	$2.612M	$2.580M	$2.234M	$2.730M	$2.770M	$2.020M	$2.150M	$2.280M	$2.430M	$2.250M	$2.040M	$1.840M	$1.420M	$950.0K	$640.0K	$390.0K	$240.0K
YoY Change	1.24%	15.49%	-18.17%	-1.44%	37.13%	-6.05%	-5.7%	-6.17%	8.0%	10.29%	10.87%	29.58%	49.47%	48.44%	64.1%	62.5%
% of Gross Profit	66.16%	336.81%		580.85%	659.52%				177.37%	58.14%	28.49%	24.47%	23.13%	14.07%	12.72%	18.22%	120.0%
Operating Expenses	$30.46M	$31.21M	$25.32M	$25.28M	$21.46M	$18.97M	$20.81M	$19.85M	$19.23M	$19.08M	$15.79M	$10.68M	$9.210M	$8.730M	$4.710M	$6.540M	$4.110M
YoY Change	-2.41%	23.25%	0.16%	17.8%	13.13%	-8.84%	4.84%	3.22%	0.79%	20.84%	47.85%	15.96%	5.5%	85.35%	-27.98%	59.12%
Operating Profit	-$26.51M	-$30.44M	-$30.87M	-$24.81M	-$21.04M	-$19.92M	-$21.91M	-$21.07M	-$17.86M	-$15.21M	-$8.630M	-$3.160M	-$3.070M	-$1.980M	$320.0K	-$4.400M	-$3.910M
YoY Change	-12.92%	-1.38%	24.41%	17.92%	5.62%	-9.08%	3.99%	17.97%	17.42%	76.25%	173.1%	2.93%	55.05%	-718.75%	-107.27%	12.53%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Interest Expense	$521.0K	-$2.813M	$979.0K	-$1.360M	$2.130M	-$650.0K	$1.250M	$1.690M	$1.240M	$1.020M	-$70.00K	$780.0K	$3.830M	-$5.220M	-$4.860M	-$440.0K	-$1.200M
YoY Change	-118.52%	-387.33%	-171.99%	-163.85%	-427.69%	-152.0%	-26.04%	36.29%	21.57%	-1557.14%	-108.97%	-79.63%	-173.37%	7.41%	1004.55%	-63.33%
% of Operating Profit															-1518.75%
Other Income/Expense, Net	$0.00	$3.500M	-$458.0K		-$50.00K	-$140.0K	-$130.0K	-$160.0K	-$200.0K	-$200.0K	-$90.00K	-$70.00K	$0.00	$230.0K	$1.130M	-$260.0K	$240.0K
YoY Change	-100.0%	-864.19%			-64.29%	7.69%	-18.75%	-20.0%	0.0%	122.22%	28.57%		-100.0%	-79.65%	-534.62%	-208.33%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Pretax Income	-$25.99M	-$29.75M	-$30.43M	-$26.17M	-$19.09M	-$20.78M	-$20.83M	-$19.56M	-$17.21M	-$14.53M	-$8.880M	-$2.450M	$650.0K	-$6.970M	-$3.410M	-$5.110M	-$4.880M
YoY Change	-12.66%	-2.23%	16.29%	37.09%	-8.13%	-0.24%	6.49%	13.65%	18.44%	63.63%	262.45%	-476.92%	-109.33%	104.4%	-33.27%	4.71%
Income Tax	-$33.00K	$90.00K	$13.00K	$30.00K	$20.00K	$30.00K	$10.00K	$40.00K		$0.00	$0.00	$70.00K	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income													0.0%
Net Earnings	-$23.88M	-$26.64M	-$27.79M	-$23.37M	-$18.11M	-$20.76M	-$20.84M	-$19.59M	-$17.21M	-$14.53M	-$8.880M	-$2.520M	$650.0K	-$6.970M	-$3.410M	-$5.110M	-$4.880M
YoY Change	-10.36%	-4.16%	18.93%	29.04%	-12.76%	-0.38%	6.38%	13.83%	18.44%	63.63%	252.38%	-487.69%	-109.33%	104.4%	-33.27%	4.71%
Net Earnings / Revenue	-423.39%	-1590.33%	-2988.49%	-2247.12%	-2414.67%	-1186.29%	-616.57%	-299.54%	-154.63%	-100.14%	-50.51%	-14.76%	4.36%	-55.49%	-34.13%	-140.38%	-1952.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.52	-$0.65	-$687.4K	-$829.9K	-$703.3K	-$806.2K	-$811.8K	-$770.0K	-$678.1K	-$578.9K	-$454.7K	-$136.8K	$34.70K	-$535.3K	-$260.1K	-$513.6K	-$575.5K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash & Short-Term Investments	$31.06M	$35.36M	$53.87M	$48.20M	$46.90M	$54.50M	$71.80M	$88.10M	$100.6M	$115.3M	$126.9M	$55.10M	$58.80M	$35.80M	$38.20M	$29.60M	$9.200M
YoY Change	-12.14%	-34.36%	11.76%	2.77%	-13.94%	-24.09%	-18.5%	-12.43%	-12.75%	-9.14%	130.31%	-6.29%	64.25%	-6.28%	29.05%	221.74%
Cash & Equivalents	$20.77M	$28.98M	$32.33M	$46.20M	$34.70M	$5.800M	$0.00	$1.200M	$7.300M	$1.100M	$82.50M	$18.40M	$1.000M	$9.000M	$26.20M	$14.60M	$8.700M
Short-Term Investments	$10.29M	$6.375M	$21.54M	$2.000M	$12.10M	$48.70M	$68.30M	$84.90M	$90.40M	$110.1M	$31.50M	$30.90M	$52.30M	$25.70M	$12.00M	$15.00M	$600.0K
Other Short-Term Assets						$300.0K	$200.0K	$200.0K	$200.0K	$1.200M	$200.0K	$300.0K	$300.0K	$200.0K
YoY Change						50.0%	0.0%	0.0%	-83.33%	500.0%	-33.33%	0.0%	50.0%
Inventory	$76.00K	$566.0K	$92.00K
Prepaid Expenses
Receivables	$357.0K	$348.0K	$281.0K	$200.0K	$100.0K	$200.0K	$100.0K	$200.0K	$2.700M	$1.200M	$1.900M	$1.500M	$800.0K	$2.100M	$600.0K	$1.900M	$0.00
Other Receivables	$2.973M	$1.482M	$2.651M	$3.400M	$2.100M	$500.0K	$700.0K	$1.000M	$800.0K	$700.0K	$500.0K	$400.0K	$700.0K	$400.0K	$300.0K	$300.0K	$400.0K
Total Short-Term Assets	$34.47M	$37.75M	$56.89M	$51.80M	$49.00M	$55.50M	$72.80M	$89.50M	$104.4M	$118.4M	$129.6M	$57.30M	$60.60M	$38.50M	$39.10M	$31.80M	$9.600M
YoY Change	-8.69%	-33.64%	9.83%	5.71%	-11.71%	-23.76%	-18.66%	-14.27%	-11.82%	-8.64%	126.18%	-5.45%	57.4%	-1.53%	22.96%	231.25%
Property, Plant & Equipment	$3.435M	$4.067M	$4.182M	$3.900M	$5.300M	$3.200M	$4.800M	$6.500M	$8.200M	$8.800M	$7.200M	$7.400M	$7.100M	$4.100M	$3.400M	$1.400M	$700.0K
YoY Change	-15.54%	-2.75%	7.23%	-26.42%	65.63%	-33.33%	-26.15%	-20.73%	-6.82%	22.22%	-2.7%	4.23%	73.17%	20.59%	142.86%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$28.00K	$74.00K	$25.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$400.0K	$500.0K	$0.00	$0.00	$0.00	$100.0K	$700.0K	$0.00
YoY Change	-62.16%	196.0%							-100.0%	-20.0%				-100.0%	-85.71%
Other Assets	$0.00	$94.00K
YoY Change	-100.0%
Total Long-Term Assets	$16.63M	$18.38M	$19.41M	$20.10M	$22.40M	$3.200M	$4.800M	$6.500M	$8.200M	$9.200M	$7.700M	$7.600M	$7.300M	$4.400M	$3.800M	$2.400M	$1.000M
YoY Change	-9.49%	-5.35%	-3.41%	-10.27%	600.0%	-33.33%	-26.15%	-20.73%	-10.87%	19.48%	1.32%	4.11%	65.91%	15.79%	58.33%	140.0%
Total Assets	$51.10M	$56.13M	$76.30M	$71.90M	$71.40M	$58.70M	$77.60M	$96.00M	$112.6M	$127.6M	$137.3M	$64.90M	$67.90M	$42.90M	$42.90M	$34.20M	$10.60M
YoY Change
Accounts Payable	$1.785M	$1.036M	$1.463M	$900.0K	$1.000M	$1.000M	$1.100M	$1.300M	$1.800M	$2.000M	$2.000M	$4.600M	$4.100M	$3.000M	$1.700M	$1.300M	$800.0K
YoY Change	72.3%	-29.19%	62.56%	-10.0%	0.0%	-9.09%	-15.38%	-27.78%	-10.0%	0.0%	-56.52%	12.2%	36.67%	76.47%	30.77%	62.5%
Accrued Expenses	$2.537M	$1.987M	$2.662M	$2.500M	$2.100M	$2.700M	$2.600M	$2.400M	$2.700M	$3.100M	$3.800M
YoY Change	27.68%	-25.36%	6.48%	19.05%	-22.22%	3.85%	8.33%	-11.11%	-12.9%	-18.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$853.0K	$884.0K	$974.0K	$800.0K	$900.0K
YoY Change	-3.51%	-9.24%	21.75%	-11.11%
Total Short-Term Liabilities	$6.944M	$5.625M	$6.882M	$9.700M	$5.700M	$5.400M	$4.700M	$5.200M	$5.600M	$7.900M	$8.600M	$9.500M	$9.100M	$16.30M	$5.800M	$3.300M	$800.0K
YoY Change	23.45%	-18.27%	-29.05%	70.18%	5.56%	14.89%	-9.62%	-7.14%	-29.11%	-8.14%	-9.47%	4.4%	-44.17%	181.03%	75.76%	312.5%
Long-Term Debt	$10.65M	$11.05M	$1.695M	$1.700M	$2.100M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.000M	$3.500M	$7.800M	$5.600M	$3.500M
YoY Change	-3.56%	551.68%	-0.29%	-19.05%								-100.0%	-14.29%	-55.13%	39.29%	60.0%
Other Long-Term Liabilities	$4.819M	$4.665M	$4.307M	$3.700M	$3.300M	$3.000M	$3.600M	$3.500M	$3.200M	$3.600M	$4.000M	$7.100M	$7.700M	$6.300M	$10.00M	$15.60M	$600.0K
YoY Change	3.3%	8.31%	16.41%	12.12%	10.0%	-16.67%	2.86%	9.38%	-11.11%	-10.0%	-43.66%	-7.79%	22.22%	-37.0%	-35.9%	2500.0%
Total Long-Term Liabilities	$15.47M	$15.71M	$6.002M	$5.400M	$5.400M	$3.000M	$3.600M	$3.500M	$3.200M	$3.600M	$4.000M	$7.100M	$10.70M	$9.800M	$17.80M	$21.20M	$4.100M
YoY Change	-1.52%	161.76%	11.15%	0.0%	80.0%	-16.67%	2.86%	9.38%	-11.11%	-10.0%	-43.66%	-33.64%	9.18%	-44.94%	-16.04%	417.07%
Total Liabilities	$39.05M	$28.20M	$22.65M	$25.90M	$21.20M	$8.600M	$8.200M	$8.700M	$8.800M	$11.50M	$12.60M	$16.60M	$19.80M	$26.10M	$23.50M	$24.50M	$5.000M
YoY Change	38.49%	24.48%	-12.54%	22.17%	146.51%	4.88%	-5.75%	-1.14%	-23.48%	-8.73%	-24.1%	-16.16%	-24.14%	11.06%	-4.08%	390.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $7.8335 Million

About Evogene Ltd.

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Industry: Agricultural Chemicals Peers: Chemomab Therapeutics Ltd. Enlivex Therapeutics Ltd. CollPlant Biotechnologies Ltd Protalix BioTherapeutics, Inc. Entera Bio Ltd.